Adaptimmune Therapeutics plc (ADAP)

Adaptimmune Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	147.02	109.6	151.67	61.48	54.91
Short-Term Investments	2.95	96.57	219.63	311.34	39.13
Cash & Cash Equivalents	149.96	206.17	371.3	372.82	94.04
Cash Growth	-27.26%	-44.47%	-0.41%	296.46%	-55.06%
Receivables	0.82	7.44	0.75	0.14	0
Other Current Assets	56.77	41.76	43.41	25.19	26.45
Total Current Assets	207.55	255.37	415.46	398.15	120.49
Property, Plant & Equipment	71.71	71.54	51.37	46.66	51.86
Goodwill and Intangibles	0.33	0.44	1	1.73	2.2
Other Long-Term Assets	3.03	1.57	1.72	4.6	7
Total Long-Term Assets	75.06	73.55	54.09	52.99	61.05
Total Assets	282.62	328.92	469.55	451.14	181.54
Accounts Payable	8.13	4.75	8.11	6.39	6.36
Deferred Revenue	178.03	184.41	199.42	52.09	2.13
Current Debt	5.38	2.73	2.32	2.77	2.49
Other Current Liabilities	-118.76	-127.39	-147.31	-22.18	23.36
Total Current Liabilities	72.79	64.5	62.54	39.07	34.34
Long-Term Debt	19.85	20.35	23.15	20.94	22.97
Other Long-Term Liabilities	150.46	162.19	177.9	49.9	0.6
Total Long-Term Liabilities	170.32	182.54	201.04	70.84	23.56
Total Liabilities	243.1	247.04	263.59	109.92	57.91
Total Debt	25.24	23.08	25.47	23.71	25.46
Debt Growth	9.35%	-9.39%	7.41%	-6.87%	-
Retained Earnings	-1,023.17	-909.3	-743.85	-585.76	-455.66
Comprehensive Income	-3.75	-0.88	-11.14	-10.05	-7.26
Shareholders' Equity	39.51	81.88	205.96	341.23	123.64
Net Cash / Debt	124.73	183.1	345.83	349.11	68.58
Net Cash / Debt Growth	-31.88%	-47.06%	-0.94%	409.06%	-67.22%
Net Cash Per Share	0.10	0.19	0.37	0.41	0.11
Working Capital	134.76	190.87	352.92	359.08	86.15
Book Value Per Share	0.20	0.51	1.32	2.40	1.18

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).